On video: the operation of the corona vaccine in Israel/photo: Reuters
A new study on corona vaccines that examined nearly 100 million vaccinated people showed small but existing links to vaccines previously observed for an increased risk of certain side effects, including inflammation of the heart muscle and Guillain-Barré syndrome, which causes temporary paralysis.
The study was conducted by the Global COVID Vaccine Safety Project and took into account 99,068,901 vaccinated people in eight countries: Argentina, Australia, Canada, Denmark, Finland, France, New Zealand and Scotland.
The report specifically looked at side effects following the administration of the Pfizer, Moderna and AstraZeneca vaccines.
The researchers looked for 13 health events of special interest that occurred up to 42 days after the vaccines were administered. These conditions included Guillain-Barre syndrome, Bell's palsy, seizures , myocarditis and pericarditis.
A new corona vaccine for the Omicron variety / Reuven Castro
The researchers observed a "significant increase" in cases of Guillain-Barre syndrome among those who received the AstraZeneca vaccine after 42 days.
They also noted higher-than-expected cases of acute disseminated encephalitis (ADEM), an inflammation of the brain and spinal cord, among those who received the first dose of Moderna's vaccine.
However, the study noted that with regard to acute disseminated encephalitis - there was "no consistent pattern in terms of vaccination or timing following vaccination, and larger epidemiological studies have not confirmed any possible association".
Both the mRNA vaccines from Pfizer and Moderna were associated with cases of myocarditis, an inflammation of the heart muscle, that occurred more than expected in the study and consistently after the first, second, and third vaccinations.
Significantly higher than expected cases of inflammation of the heart muscle - pericarditis - inflammation of the sac-like structure that surrounds the heart, were also observed after the first and fourth dose of Moderna's vaccine.
"The safety signals identified in this study should be evaluated in the context of their rarity, severity, and clinical relevance," the researchers wrote.
"Furthermore, overall risk-benefit assessments of vaccination should take into account the risk associated with infection, as many studies have demonstrated a higher risk of developing the events being tested, such as myocarditis or acute disseminated encephalitis, following SARS-CoV-2 infection."
More on the same topic:
Corona vaccine
Corona
meningitis